Clinical trials: Advanced Gastrointestinal Cancer, open to volunteers
Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer
This study is a single-arm, open-label, exploratory clinical trial. Building on the previous dose-escalation trial, this dose-expansion trial aims to evaluate the safety and tolerability of intravenous monotherapy with CD-GA-102…
- Conditions
- Colorectal Cancer Metastatic, Colorectal Cancer Recurrent, Colorectal Cancer Stage IV
- Trial name
- NCT07050394
- Testing
- CD-GA-102
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Changzheng Hospital
Esophageal Cancer, Nimotuzumab
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) who failed to induction chemo(immuno)therapy had poor prognosis. Radiotherpy was an important and effective treatment in treating ESCC.
- Conditions
- Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
- Trial name
- NCT06410651
- Testing
- Nimotuzumab with chemoradiotherapy
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Cancer, Peritoneal Metastases
HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy
Patients with stage cT3-4N+M0 gastric cancer were recommended to receive neoadjuvant chemotherapy before radical surgery in terms of the eradication of micrometastasis in addition to local control, higher compliance with…
- Trial name
- NCT05300945
- Testing
- HIPEC
- Volunteers
- 200 people
- Sponsor
- Zhixin Cao
Esophageal Cancer
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma (ESCC). Aim to evaluate the efficacy and safety of Iparomlimab consolidation therapy following concurrent…
- Trial name
- NCT07038629
- Testing
- S1, Iparomlimab, Radiation
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colo-rectal Cancer
EMVI as a Determinant of Metastasis in Colorectal Cancer
Bowel cancer is the fourth most commonly occurring cancer and the second highest cause of cancer deaths in the UK. Despite advances in treatment, over 40% of patients will die within 5 years.
- Trial name
- EVIDENCE (NCT06646341)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Esophageal Squamous Cell Cancer
Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
The goal of this clinical trial is to evaluate the efficacy and safety of retlirafusp alfa combined with radical chemoradiotherapy in the treatment of locally advanced unresectable esophageal squamous cell carcinoma.
- Trial name
- NCT07769866
- Testing
- Induction chemo-immunotherapy, Concurrent chemoradiotherapy (cCRT), maintenance immunotherapy
- Where
- China
- Volunteers
- 68 people
- Sponsor
- RenJi Hospital
Non-Small Cell Lung Cancer, NSCLC
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
- Trial name
- NCT06917079
- Testing
- BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin)
- Where
- 17 sites in United States, Australia
- Volunteers
- 665 people
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Pancreatic Cancer
CAR-NK Cells (CL-NK-003) in Pancreatic Cancer
This is a single-center, open-label, first-in-human, fixed-dose study in patients with pancreatic cancer.
- Trial name
- NCT07425483
- Testing
- CL-NK-003
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Changhai Hospital
Gastric Carcinoma, Gastric Neoplasm
The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer
Compared with other anti-tumor drugs, immune checkpoint inhibitors (ICIs) have their own unique pharmacokinetics (PK) and pharmacodynamics (PD), and affect patient clinical outcomes.
- Conditions
- Gastric Carcinoma, Gastric Neoplasm, Gastric (cardia, Body) Cancer, Gastric Cancer Adenocarcinoma Metastatic
- Trial name
- NCT06702683
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Lin Liu
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
Colorectal Cancer
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
This study is an open, multi-center, phase II study, aiming to evaluate the safety, tolerability and efficacy of AMT-676 combined with 5-fluorouracil, leucovorin, bevacizumab (or cetuximab) in participants with advanced…
- Trial name
- NCT07474727
- Testing
- AMT-676, 5-FU, Leucovorin
- Where
- 19 sites in China
- Volunteers
- 180 people
- Sponsor
- Multitude Therapeutics Inc.
Rectal Cancer
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
The goal of this Phase 2 trial is to evaluate a neoadjuvant treatment mode for locally advanced rectal cancer (LARC), consisting of radiotherapy and concurrent Trifluridine/Tipiracil (TAS-102).
- Trial name
- TASLARC (NCT05965531)
- Testing
- Trifluridine/Tipiracil, intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer
Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy
This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.
- Trial name
- EASOPCWAAC (NCT06586242)
- Testing
- Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Xijing Hospital
Colorectal Cancer
The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer
To evaluate the efficacy and safety of TAS-102 combined with bevacizumab as first-line therapy in patients with advanced colorectal cancer who could not tolerate or did not receive combined chemotherapy
- Trial name
- NCT06092242
- Testing
- Tas-102(Suyuan) combined with bevacizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Colorectal Carcinoma
Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer
Efficacy Study of Digoxin Combined with Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer
- Trial name
- NCT07025850
- Testing
- Digoxin, Fuquinitinib, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Liver Cirrhosis
Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)
This prospective multicenter observational study evaluates the performance of a structured hepatocellular carcinoma (HCC) surveillance program in patients at increased risk of developing liver cancer.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Hepatitis B, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- Screening HCC (NCT07764835)
- Volunteers
- 300 people
- Sponsor
- D'Or Institute for Research and Education
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Locally Advanced Rectal Cancer
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
This trial is a multicenter randomized Phase III study to verify the superiority of short-course preoperative radiation (SCRT) and CAPOXIRI over SCRT and CAPOX as preoperative treatments for locally advanced rectal cancer.
- Trial name
- ENSEMBLE (NCT05646511)
- Testing
- SCRT, CAPOX, CAPOXIRI
- Where
- 34 sites in Japan
- Volunteers
- 608 people
- Sponsor
- National Cancer Center Hospital East
Advanced Hepatocellular Carcinoma
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
The goal of this investigator-initiated, a single-arm, open-label, pilot study is to investigate the safety, tolerability, and efficacy of Intravenous CD-801 treatment in subjects with advanced hepatocellular carcinoma(HCC).
- Trial name
- NCT06418659
- Testing
- CD-801
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shanghai Changzheng Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.